Market News
Eli Lilly’s Q2 2025: Mounjaro, Zepbound Drive Growth
Eli Lilly's Q2 2025 earnings beat expectations with blockbuster drug sales. But what’s next for their obesity pill trials? Click...
07/08/2025
2 views